LSA
MRTX

L & S Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

L & S Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,000
Closed -$220K – 406
2020
Q4 		$220K Buy
+1,000
New +$216K 0.03% 313

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

L & S Advisors's MRTX Position: Q1 2021 in Review

L & S Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2021, closing a stake of 1,000 shares — an estimated $220K sold.

L & S Advisors first reported a position in MRTX in Q4 2020 and held it in 1 quarter. The position peaked at $220K in Q4 2020. 260 funds tracked by Wall St. Rank hold MRTX as of Q1 2021.

  • L & S Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • L & S Advisors sold 1,000 Mirati Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $220K.
  • L & S Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • L & S Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $220K in Q4 2020.
  • 260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2021.

Based on L & S Advisors's 13F filing for Q1 2021, filed 10 May 2021.